Overcoming barriers to effective management of tardive dyskinesia

Stanley N Caroff Corporal Michael J Crescenz VA Medical Center, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Tardive dyskinesia (TD) is a heterogeneous syndrome of involuntary hyperkinetic movements that is often persistent and occurs belatedly d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Caroff SN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	tardive dyskinesia valbenazine deutetrabenazine vesicular monoamine transporter inhibitors antipsychotics schizophrenia bipolar disorder major depressive disorder drug-induced movement disorders Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/cfac4fa9d4fa4708a476b4cf58db1703
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfac4fa9d4fa4708a476b4cf58db1703
record_format	dspace
spelling	oai:doaj.org-article:cfac4fa9d4fa4708a476b4cf58db17032021-12-02T05:19:07ZOvercoming barriers to effective management of tardive dyskinesia1178-2021https://doaj.org/article/cfac4fa9d4fa4708a476b4cf58db17032019-04-01T00:00:00Zhttps://www.dovepress.com/overcoming-barriers-to-effective-management-of-tardive-dyskinesia-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Stanley N Caroff Corporal Michael J Crescenz VA Medical Center, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Tardive dyskinesia (TD) is a heterogeneous syndrome of involuntary hyperkinetic movements that is often persistent and occurs belatedly during treatment with antipsychotics. Recent approval of two dopamine-depleting analogs of tetrabenazine based on randomized controlled trials offers an evidence-based therapeutic approach to TD for the first time. These agents are optimally used within the context of a comprehensive approach to patient management that includes a practical screening and monitoring program, sensitive and specific criteria for the diagnosis of TD, awareness of the severity and impact of the disorder, informed discussions with patients and caregivers, and a rational basis for prescribing decisions about continued antipsychotic and adjunctive agents. Areas of limited or inconclusive data, bias and misunderstandings about key aspects, and neglect of training about TD in recent years contribute to barriers in providing effective care and promoting patient safety. Keywords: tardive dyskinesia, valbenazine, deutetrabenazine, tetrabenazine vesicular monoamine transporter inhibitors, antipsychotics, schizophrenia, bipolar disorder, major depressive disorder, drug-induced movement disorders  Caroff SNDove Medical Pressarticletardive dyskinesiavalbenazinedeutetrabenazinevesicular monoamine transporter inhibitorsantipsychoticsschizophreniabipolar disordermajor depressive disorderdrug-induced movement disordersNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 785-794 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	tardive dyskinesia valbenazine deutetrabenazine vesicular monoamine transporter inhibitors antipsychotics schizophrenia bipolar disorder major depressive disorder drug-induced movement disorders Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	tardive dyskinesia valbenazine deutetrabenazine vesicular monoamine transporter inhibitors antipsychotics schizophrenia bipolar disorder major depressive disorder drug-induced movement disorders Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Caroff SN Overcoming barriers to effective management of tardive dyskinesia
description	Stanley N Caroff Corporal Michael J Crescenz VA Medical Center, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Tardive dyskinesia (TD) is a heterogeneous syndrome of involuntary hyperkinetic movements that is often persistent and occurs belatedly during treatment with antipsychotics. Recent approval of two dopamine-depleting analogs of tetrabenazine based on randomized controlled trials offers an evidence-based therapeutic approach to TD for the first time. These agents are optimally used within the context of a comprehensive approach to patient management that includes a practical screening and monitoring program, sensitive and specific criteria for the diagnosis of TD, awareness of the severity and impact of the disorder, informed discussions with patients and caregivers, and a rational basis for prescribing decisions about continued antipsychotic and adjunctive agents. Areas of limited or inconclusive data, bias and misunderstandings about key aspects, and neglect of training about TD in recent years contribute to barriers in providing effective care and promoting patient safety. Keywords: tardive dyskinesia, valbenazine, deutetrabenazine, tetrabenazine vesicular monoamine transporter inhibitors, antipsychotics, schizophrenia, bipolar disorder, major depressive disorder, drug-induced movement disorders
format	article
author	Caroff SN
author_facet	Caroff SN
author_sort	Caroff SN
title	Overcoming barriers to effective management of tardive dyskinesia
title_short	Overcoming barriers to effective management of tardive dyskinesia
title_full	Overcoming barriers to effective management of tardive dyskinesia
title_fullStr	Overcoming barriers to effective management of tardive dyskinesia
title_full_unstemmed	Overcoming barriers to effective management of tardive dyskinesia
title_sort	overcoming barriers to effective management of tardive dyskinesia
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/cfac4fa9d4fa4708a476b4cf58db1703
work_keys_str_mv	AT caroffsn overcomingbarrierstoeffectivemanagementoftardivedyskinesia
_version_	1718400499029377024

Overcoming barriers to effective management of tardive dyskinesia

Ejemplares similares